A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Drögemöller BI, Wright GEB, Trueman J et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Ondansetron is a highly effective antiemetic for the treatment of nausea and vomiting. However, this medication has also been associated with QT prolongation. Pharmacogenomic information on therapeutic response to ondansetron exists, but no investigation has been performed on genetic factors that influence the cardiac safety of this medication.
62 Admixed, Admixed American, African, East Asian, European, First Nations, Middle Eastern, South Asian, South East Asian or unknown ancestry cases, 195 Admixed, Admixed American, African, East Asian, European, First Nations, Middle Eastern, South Asian, South East Asian or unknown ancestry controls
Study Statistics
Key metrics and study information
Analysis
Comprehensive review of health and genetic findings
Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.
Analysis In Progress
Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.